186 related articles for article (PubMed ID: 31382782)
1. Clinical and prognostic effects of
Xia L; Zhang W; Gao L
Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
[No Abstract] [Full Text] [Related]
2. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
3. Modified CDKN2B (p15) and CDKN2A (p16) DNA methylation profiles in urban pesticide applicators.
Herrera-Moreno JF; Medina-Díaz IM; Bernal-Hernández YY; Ramos KS; Alvarado-Cruz I; Quintanilla-Vega B; González-Arias CA; Barrón-Vivanco BS; Rojas-García AE
Environ Sci Pollut Res Int; 2019 May; 26(15):15124-15135. PubMed ID: 30924039
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
Yang J; Niu H; Huang Y; Yang K
PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
[TBL] [Abstract][Full Text] [Related]
6. Role of CDH13 promoter methylation in the carcinogenesis, progression, and prognosis of colorectal cancer: A systematic meta-analysis under PRISMA guidelines.
Ye M; Huang T; Li J; Zhou C; Yang P; Ni C; Chen S
Medicine (Baltimore); 2017 Jan; 96(4):e5956. PubMed ID: 28121942
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Arya AK; Bhadada SK; Singh P; Sachdeva N; Saikia UN; Dahiya D; Behera A; Bhansali A; Rao SD
Sci Rep; 2017 Jun; 7(1):3123. PubMed ID: 28600574
[TBL] [Abstract][Full Text] [Related]
8. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
[TBL] [Abstract][Full Text] [Related]
9. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
11. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.
Chim CS; Kwong YL
Leuk Lymphoma; 2006 May; 47(5):815-25. PubMed ID: 16753865
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between methylation level of
Zheng Z; Ji H; Chen C; Li Y; Duan S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):724-730. PubMed ID: 31270053
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.
Zhang W; Kuang P; Liu T
Ann Med; 2019 Feb; 51(1):28-40. PubMed ID: 30592434
[TBL] [Abstract][Full Text] [Related]
14. Methylation patterns of the
Paredes-Céspedes DM; Bernal-Hernández YY; Herrera-Moreno JF; Rojas-García AE; Medina-Díaz IM; González-Arias CA; Barrón-Vivanco BS
Hum Exp Toxicol; 2022; 41():9603271211063161. PubMed ID: 35067100
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Fu HY; Shen JZ; Wu Y; Shen SF; Zhou HR; Fan LP
Oncol Rep; 2010 Aug; 24(2):335-43. PubMed ID: 20596618
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
Guney S; Bertrand P; Jardin F; Ruminy P; Kerckaert JP; Tilly H; Bastard C
Genes Chromosomes Cancer; 2011 Sep; 50(9):715-25. PubMed ID: 21638516
[TBL] [Abstract][Full Text] [Related]
18. [Methylation of the genes in the 9P21 region in children with acute myeloid leukemia].
Zhang L; Ruan M; Liu XM; Zhang JY; Guo Y; Yang WY; Liu F; Liu TF; Wang SC; Chen XJ; Zou Y; Chen YM; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):6-10. PubMed ID: 25616284
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer.
Zhong YH; Peng H; Cheng HZ; Wang P
Asian Pac J Cancer Prev; 2015; 16(3):1139-43. PubMed ID: 25735345
[TBL] [Abstract][Full Text] [Related]
20. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
